15/02/2019
Marie Skłodowska-Curie Actions

Marie Skłodowska-Curie fellows NEXT CALL MSCA-IF-2019

Save to favorites

  • ORGANISATION NAME
    FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA
  • ORGANISATION COUNTRY
    Spain
  • FUNDING TYPE
    Funding
    Mobility Incoming
  • DEADLINE DATE
    14/09/2019
  • RESEARCH FIELD
    Natural sciences
  • CAREER STAGE
    Recognised Researcher (R2) (PhD holders or equivalent who are not yet fully independent)
    Established Researcher (R3) (Researchers who have developed a level of independence)

Hosting Institution: Center for Applied Medical Research (CIMA), University of Navarra.

 

Person of contact and email:  Luis M. Montuenga lmontuenga@unav.es  (Please CC P.A. Marisol Ripa msripa@unav.es)

Outline

The Laboratory of Biomarkers and New Therapeutic Targets in Lung Cancer of the Center of Applied Medical Research (CIMA ) is interested in how genetic and phenotypic alterations in lung cancer cells contribute to tumorigenesis, alter treatment response, or create vulnerabilities that may be targeted therapeutically. We are also interested in leveraging these data for development of biomarkers for early diagnosis, prognosis or prediction of treatment response, including immunotherapeutic agents.  The ultimate goal of our group at CIMA/CIBERONC is to improve our understanding of lung cancer and to identify novel strategies that can be exploited diagnostically, prognostically or therapeutically.

Research/Project description

Specific aims of our group are to understand how genetic/phenotypic alterations in lung cancer cells drive carcinogenesis at early stages; how these alterations influence the microenvironment and immune landscape; how they may be targeted by small molecules or other immune-based strategies; and how they may affect mechanisms of (immune) escape and response to therapy.

Our research involves both molecular pathological analysis of human tumor samples and in vitro and in vivo (including cell and animal) systems for the study of lung cancer, as well as the identification of drug targets for disease management. Molecular and imaging technologies as well as genetic and epigenetic profiling approaches are used.

 

We have a large collection of very well clinically characterized human normal and tumor samples as part of the lung cancer multidisciplinary area of the Clínica Universidad de Navarra. Three cohorts are available: high risk individuals included in a CT-screening project; resected specimens from early (stage I-IIIa) cases; and late stage patients treated with a variety of treatments, including targeted therapies and immunotherapies.  

The project will be to identify and determine the role of specific (epi)genetic or phenotypic changes as drivers of lung carcinogenesis or metastasis, together with potential effect of microenvironmental/immune interactions in these carcinogenic traits. We also want to explore inhibitory strategies and resistance mechanisms. Single cell and multiplex analysis, in particular image-based, are in our current interest. Translational focus will be always present.

What is funded

The awardee will have a full-time contract in the Center for Apllied Medical Research according to his/her research category, comprising Living, Mobility, and Family allowance (see description in the EC call webpage http://ec.europa.eu/research/mariecurieactions/).

Category level and salary will be determined in the formal offer after evaluation of scientific merits of the candidate. CIMA has a career development system based on 2 “tenure track” (colaborador de investigación), 5 “researcher” and 2 “senior researcher” levels.

Duration

The Grant funds for 24 months. Additions can be considered depending on achievements of results.

Eligibility

General requirements:

At the deadline for the submission of proposals (DEADLINE), the candidate (*):

  • Shall be in possession of a doctoral degree or have at least four years of full-time equivalent research experience.
  • Must not have resided or carried out his/her main activities in Spain for more than 12 months in the 3 years (36 months) immediately prior to the abovementioned deadline.

 

Scientific requirements

We would be particularly interested in scientists with experience in molecular pathology and imaging in cancer, and in multiplex cell-based assays for characterization of tissues, but will gladly consider other varied types of expertise. 

 

We are accepting applications from talented and enthusiastic candidates who are interested in a dynamic, well-supported lab at a top research Spanish institution. The successful candidate must have a Ph.D. in molecular biology, cell biology, immunology or a related topic plus a minimum of 4 years of postdoctoral research experience in high quality Spanish or international research centers in oncology-related areas. First or relevant authorship publications in high-impact factor journals and experience in grant application writing is also a requisite.

 

Ideally, the candidate must have supervised at least one MSc/PhD student and had been PI or Co-PI at least in one competitive starting grant. Technical experience in general molecular biology, cell culture, and histological techniques are required. We also value candidates with knowledge on management of mouse colonies, flow cytometry, basic computational skills, immunology, and drug efficacy studies. Having skills in molecular pathology, diagnostics or basic histopathology experience, bio-banking and imaging will be considered favorably.

The candidate is expected to work actively and with independence in a collaborative environment, and to have strong communication skills in Spanish and/or English.

 

Specific requirements:

  • A Curriculum Vitae
  • Summary presentation of the candidate’s research proposal and expertise that he/she would bring to the institution (maximum extension 9 pages).
  • A motivation letter (1 page)

Contact information of  3  referees

More Information

Disclaimer:

The responsibility for the funding offers published on this website, including the funding description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.